News

Apricus’ Investigational Treatment for Raynaud’s Phenomenon Receives Notice of Allowance of U.S. Patent Application

The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application to RayVa, a product candidate being developed by Apricus Biosciences for the treatment of Raynaud’s phenomenon, including the treatment of the condition secondary to Scleroderma. The Notice of Allowance means that the USPTO is now…

Tissue Scarring in Scleroderma Linked To Key Protein

A study entitled “FibronectinEDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor Signaling” recently published in Science Translational Medicine reports the discovery of the role of a new protein, fibronectin extra domain A, in scleroderma. The discovery may explain what causes the onset of the disease…

Aberrant Cell Pathways Lead to Scleroderma Skin Manifestations

Systemic sclerosis, often characterized by thickened skin and connective tissue, may be a result of increased signaling pathways. According to a study from University College London Medical School and the Musculoskeletal Biology University of Liverpool, published online ahead of print in Arthritis & Rheumatism, an increase in mTOR/AKT signaling…

Environment May Contribute to GI Involvement in Scleroderma

In 90% of all scleroderma patients, gastrointestinal (GI) tract problems lead to uncomfortable and dangerous complications. Malnutrition, nausea, vomiting, and diarrhea are among the symptoms that plague GI tract-involved scleroderma patients. Understanding how these problems develop could lead to large gains in quality of life of affected patients and…

Scleroderma Hinted at Through Joint Health

A new study entitled “Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study,” published in August issue of Annals of the Rheumatic Diseases, reports joint synovitis and tendon friction rubs can predict for early Systemic sclerosis progression. In this study,…